{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-063077","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.829620+00:00","generated_at":"2026-06-18T09:47:14.990751+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DBV screens first patient in VITESSE Phase 3 peanut allergy trial for ages 4–7","bullets":["First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois for VITESSE Phase 3 trial.","Trial enrolls 600 children ages 4–7, randomized 2:1 active (Viaskin Peanut 250 µg) vs placebo.","Primary efficacy endpoint is treatment response rate at Month 12; last patient screening expected 1H 2024.","Topline results anticipated in 1H 2025; FDA supports study to potentially support BLA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-063077","json":"https://secwatch.observer/filing/0001193125-23-063077.json","markdown":"https://secwatch.observer/filing/0001193125-23-063077.md","text":"https://secwatch.observer/filing/0001193125-23-063077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523063077/0001193125-23-063077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523063077/d471482d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:47:14.990751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}